Literature DB >> 16607149

Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease.

Ioannis S Elefsiniotis1, Michael Skounakis, Elena Vezali, Konstantinos D Pantazis, Aikaterini Petrocheilou, Maria Pirounaki, George Papatsibas, Chrysa Kontou-Kastellanou, Antonios Moulakakis.   

Abstract

OBJECTIVE: To evaluate the diagnostic value of serum procalcitonin levels in patients with acute or chronic liver disease, with or without bacterial infections and to correlate the results with the clinical outcome and the laboratory findings for these patients.
METHODS: One hundred and six consecutive hospitalized patients with liver disease were evaluated for procalcitonin levels on admission. Fifteen of them (14.2%) had acute alcoholic hepatitis on cirrhotic background (group A), 20 (18.9%) had alcoholic cirrhosis without hepatitis and/or bacterial infection (group B), 16 (15.1%) had decompensated cirrhosis with proved bacterial infection (group C), 42 (39.6%) had uncomplicated viral hepatitis-related cirrhosis (group D) and 13 (12.3%) had acute icteric viral hepatitis (group E). Serum procalcitonin levels were measured using an immunoluminometric assay. Statistical analysis was based on Student's t-test and the non-parametric Kruskall-Wallis test (P<0.05).
RESULTS: Serum procalcitonin levels were significantly higher in cirrhotic patients with bacterial infection (9.80+/-16.80 ng/ml) than in those without bacterial infection (0.21+/-0.13 ng/ml, P=0.001), whereas they were within normal range (<0.5 ng/ml) in all patients with uncomplicated cirrhosis, irrespective of the cause of cirrhosis. Seven of 15 group A patients (46.2%) and 4/13 group E patients (30.8%), all of them cirrhotics, had procalcitonin levels higher than 0.5 ng/ml on admission, without established bacterial infection.
CONCLUSION: Serum procalcitonin levels remain below the threshold of 0.5 ng/ml in all patients with uncomplicated cirrhosis, irrespective of the cause of the disease, while they are significantly elevated when bacterial infection complicates the course of the disease. A significant proportion of patients with acute alcoholic hepatitis on a cirrhotic background as well as of patients with acute on chronic viral hepatitis, without bacterial infection, exhibit serum procalcitonin levels above 0.5 ng/ml, suggesting that this cut-off value is probably not enough to discriminate between patients with or without bacterial infection within these subgroups of patients with liver disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16607149     DOI: 10.1097/00042737-200605000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  18 in total

1.  Amyloid A in Serum and Ascitic Fluid as a Novel Diagnostic Marker of Spontaneous Bacterial Peritonitis.

Authors:  Rehab Badawi; Muhammad N Asghar; Sherief Abd-Elsalam; Samah A Elshweikh; Tamer Haydara; Sherein M Alnabawy; Mahmoud Elkadeem; Walaa ElKhalawany; Samah Soliman; Reham Elkhouly; Shimaa Soliman; Mona Watany; Mai Khalif; Asem Elfert
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2020

2.  Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites.

Authors:  Bashar M Attar; Christopher M Moore; Magdalena George; Nicolae Ion-Nedelcu; Rafael Turbay; Annamma Zachariah; Guiliano Ramadori; Jawed Fareed; David H Van Thiel
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Serum Procalcitonin in Patients with Acute Liver Failure.

Authors:  Takaaki Sugihara; Masahiko Koda; Toshiaki Okamoto; Kenichi Miyoshi; Tomomitsu Matono; Kenji Oyama; Keiko Hosho; Jun-Ichi Okano; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2017-03-09       Impact factor: 1.641

4.  Procalcitonin as a marker of sepsis in alcoholic hepatitis.

Authors:  Kundan Kumar; Samir Mohindra; Mithun Raj; Gourdas Choudhuri
Journal:  Hepatol Int       Date:  2014-06-03       Impact factor: 6.047

Review 5.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

6.  Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study.

Authors:  Nevin Oruc; Omer Ozutemiz; Gul Yuce; Ulus S Akarca; Galip Ersoz; Fulya Gunsar; Yucel Batur
Journal:  BMC Gastroenterol       Date:  2009-02-17       Impact factor: 3.067

Review 7.  Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and management.

Authors:  Cyriac Abby Philips; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-07-15       Impact factor: 6.047

8.  Procalcitonin Identifies Cell Injury, Not Bacterial Infection, in Acute Liver Failure.

Authors:  Jody A Rule; Linda S Hynan; Nahid Attar; Corron Sanders; William J Korzun; William M Lee
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

9.  Procalcitonin and C-reactive protein in the diagnosis and prediction of spontaneous bacterial peritonitis associated with chronic severe hepatitis B.

Authors:  Le-Yong Yuan; Zun-Qiong Ke; Ming Wang; Yan Li
Journal:  Ann Lab Med       Date:  2013-10-17       Impact factor: 3.464

10.  Procalcitonin in liver transplantation: are high levels due to donors or recipients?

Authors:  Daniel Eyraud; Saïd Ben Ayed; Marie Laure Tanguy; Corinne Vézinet; Jean Michel Siksik; Maguy Bernard; Sylvia Fratéa; Marie Movschin; Jean-Christophe Vaillant; Pierre Coriat; Laurent Hannoun
Journal:  Crit Care       Date:  2008-07-04       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.